CO2022014134A2 - N-cianopirrolidinas con actividad como inhibidores de usp30 - Google Patents
N-cianopirrolidinas con actividad como inhibidores de usp30Info
- Publication number
- CO2022014134A2 CO2022014134A2 CONC2022/0014134A CO2022014134A CO2022014134A2 CO 2022014134 A2 CO2022014134 A2 CO 2022014134A2 CO 2022014134 A CO2022014134 A CO 2022014134A CO 2022014134 A2 CO2022014134 A2 CO 2022014134A2
- Authority
- CO
- Colombia
- Prior art keywords
- cyanopyrrolidines
- activity
- usp30
- inhibitors
- usp30 inhibitors
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title abstract 2
- 101150099494 Usp30 gene Proteins 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101000748132 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 30 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100040052 Ubiquitin carboxyl-terminal hydrolase 30 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000004065 mitochondrial dysfunction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005250.2A GB202005250D0 (en) | 2020-04-08 | 2020-04-08 | Novel compounds |
| GBGB2016607.0A GB202016607D0 (en) | 2020-10-20 | 2020-10-20 | Novel Compounds |
| PCT/EP2021/059032 WO2021204856A1 (en) | 2020-04-08 | 2021-04-07 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014134A2 true CO2022014134A2 (es) | 2022-10-31 |
Family
ID=75441909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014134A CO2022014134A2 (es) | 2020-04-08 | 2022-09-30 | N-cianopirrolidinas con actividad como inhibidores de usp30 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230119013A1 (https=) |
| EP (1) | EP4132925A1 (https=) |
| JP (1) | JP2023520727A (https=) |
| KR (1) | KR20230006487A (https=) |
| CN (1) | CN115461340A (https=) |
| AU (1) | AU2021253617A1 (https=) |
| BR (1) | BR112022020058A2 (https=) |
| CA (1) | CA3171349A1 (https=) |
| CO (1) | CO2022014134A2 (https=) |
| IL (1) | IL296998A (https=) |
| MX (1) | MX2022012578A (https=) |
| WO (1) | WO2021204856A1 (https=) |
| ZA (1) | ZA202212137B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| CN117887844B (zh) * | 2023-12-28 | 2024-08-23 | 中山大学附属第一医院 | Usp20在肝癌放疗增敏中的应用 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SG174050A1 (en) | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129371A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129365A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) * | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) * | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) * | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-04-07 JP JP2022561565A patent/JP2023520727A/ja active Pending
- 2021-04-07 US US17/914,414 patent/US20230119013A1/en not_active Abandoned
- 2021-04-07 EP EP21717825.0A patent/EP4132925A1/en not_active Withdrawn
- 2021-04-07 CA CA3171349A patent/CA3171349A1/en active Pending
- 2021-04-07 AU AU2021253617A patent/AU2021253617A1/en not_active Abandoned
- 2021-04-07 WO PCT/EP2021/059032 patent/WO2021204856A1/en not_active Ceased
- 2021-04-07 CN CN202180023434.1A patent/CN115461340A/zh active Pending
- 2021-04-07 BR BR112022020058A patent/BR112022020058A2/pt unknown
- 2021-04-07 IL IL296998A patent/IL296998A/en unknown
- 2021-04-07 MX MX2022012578A patent/MX2022012578A/es unknown
- 2021-04-07 KR KR1020227038744A patent/KR20230006487A/ko not_active Withdrawn
-
2022
- 2022-09-30 CO CONC2022/0014134A patent/CO2022014134A2/es unknown
- 2022-11-07 ZA ZA2022/12137A patent/ZA202212137B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022012578A (es) | 2022-11-07 |
| IL296998A (en) | 2022-12-01 |
| KR20230006487A (ko) | 2023-01-10 |
| CN115461340A (zh) | 2022-12-09 |
| BR112022020058A2 (pt) | 2022-11-22 |
| AU2021253617A1 (en) | 2022-12-01 |
| JP2023520727A (ja) | 2023-05-18 |
| ZA202212137B (en) | 2024-07-31 |
| EP4132925A1 (en) | 2023-02-15 |
| CA3171349A1 (en) | 2021-10-14 |
| WO2021204856A1 (en) | 2021-10-14 |
| US20230119013A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022003608A2 (es) | Cianopirrolidinas sustituidas con actividad como inhibidores de usp30 | |
| CO2022014134A2 (es) | N-cianopirrolidinas con actividad como inhibidores de usp30 | |
| CO2022017112A2 (es) | N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 | |
| IL305782A (en) | Compositions and methods for targeted delivery to cells | |
| MX2023011612A (es) | Peptidos de penetracion celular ciclicos. | |
| MX2022009056A (es) | Inhibidores de integrina ?v?6. | |
| CO2022017233A2 (es) | 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis | |
| IL287728A (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| MX2019006284A (es) | Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9). | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| MX2018005925A (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| MX2016006489A (es) | Alfa-amilasas variantes que tienen susceptibilidad reducida a la escision por proteasas y metodos de uso. | |
| CR20140586A (es) | Celulas para producir iduronato-2-sulfatasa recombinante | |
| AU201712054S (en) | A Mask | |
| MX2023002411A (es) | Celulas inmunitarias modificadas para fibrosis e inflamacion. | |
| CO7131352A2 (es) | Composiciones farmacéuticas tópicas | |
| CO2022014135A2 (es) | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil)oxazol-2-carboxamida y los derivados oxadiazol correspondientes como inhibidores de usp30 para el tratamiento de disfunción mitocondrial | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| PE20151206A1 (es) | Polipeptidos del factor vii de accion corta | |
| AU201814479S (en) | A toothbrush | |
| UY35695A (es) | Composicion para el tratamiento contra el envejecimiento de la piel | |
| PE20121537A1 (es) | Combinacion de teobromina con un descongestivo | |
| EP4239058A4 (en) | Mesenchymal stem cells that enable tumor targeting improvement and virus mass-production | |
| MX2014012506A (es) | Valvula de piston rigido que incorpora un solenoide. | |
| MX2016003650A (es) | Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica. |